Abstract
Nicotinamide adenine dinucleotide (NAD+) extends longevity in experimental organisms, raising interest in its impact on human health. De novo NAD+ biosynthesis from tryptophan is evolutionarily conserved yet considered supplanted among higher species by biosynthesis from nicotinamide (NAM). Here we show that a bottleneck enzyme in de novo biosynthesis, quinolinate phosphoribosyltransferase (QPRT), defends renal NAD+ and mediates resistance to acute kidney injury (AKI). Following murine AKI, renal NAD+ fell, quinolinate rose, and QPRT declined. QPRT+/− mice exhibited higher quinolinate, lower NAD+, and higher AKI susceptibility. Metabolomics suggested an elevated urinary quinolinate/tryptophan ratio (uQ/T) as an indicator of reduced QPRT. Elevated uQ/T predicted AKI and other adverse outcomes in critically ill patients. A phase 1 placebo-controlled study of oral NAM demonstrated a dose-related increase in circulating NAD+ metabolites. NAM was well tolerated and was associated with less AKI. Therefore, impaired NAD+ biosynthesis may be a feature of high-risk hospitalizations for which NAD+ augmentation could be beneficial.
Similar content being viewed by others
References
Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17, 679–690 (2016).
Cantó, C., Menzies, K. J. & Auwerx, J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 31–53 (2015).
Ternes, C. M. & Schönknecht, G. Gene transfers shaped the evolution of de novo NAD+ biosynthesis in eukaryotes. Genome Biol. Evol. 6, 2335–2349 (2014).
Collins, P. B. & Chaykin, S. The management of nicotinamide and nicotinic acid in the mouse. J. Biol. Chem. 247, 778–783 (1972).
Krehl, W. A., Teply, L. J., Sarma, P. S. & Elvehjem, C. A. Growth-retarding effect of corn in nicotinic acid-low rations and its counteraction by tryptophane. Science 101, 489–490 (1945).
Kleta, R. et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat. Genet. 36, 999–1002 (2004).
Cantó, C. et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012).
Wang, G. et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 1324–1334 (2014).
Williams, P. A. et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355, 756–760 (2017).
Anderson, R. M., Bitterman, K. J., Wood, J. G., Medvedik, O. & Sinclair, D. A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423, 181–185 (2003).
Gomes, A. P. et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624–1638 (2013).
Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436–1443 (2016).
Lin, S. J., Defossez, P. A. & Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2126–2128 (2000).
Verdin, E. NAD+ in aging, metabolism, and neurodegeneration. Science 350, 1208–1213 (2015).
Mills, K. F. et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24, 795–806 (2016).
Mehta, R. L. et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385, 2616–2643 (2015).
Tran, M. T. et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528–532 (2016).
Lewington, A. J., Cerdá, J. & Mehta, R. L. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 84, 457–467 (2013).
Leaf, D. E. et al. Fibroblast growth factor 23 levels associate with AKI and death in critical illness. J. Am. Soc. Nephrol. 28, 1877–1885 (2017).
Gale, E. A. et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363, 925–931 (2004).
Chen, A. C. et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med. 373, 1618–1626 (2015).
Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016).
Petley, A., Macklin, B., Renwick, A. G. & Wilkin, T. J. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44, 152–155 (1995).
Bai, P. et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13, 461–468 (2011).
Morigi, M. et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J. Clin. Invest. 125, 715–726 (2015).
Agledal, L., Niere, M. & Ziegler, M. The phosphate makes a difference: cellular functions of NADP. Redox Rep. 15, 2–10 (2010).
Kirkland, J. B. Niacin requirements for genomic stability. Mutat. Res. 733, 14–20 (2012).
Shi, H. et al. NAD deficiency, congenital malformations, and niacin supplementation. N. Engl. J. Med. 377, 544–552 (2017).
Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 16, 279–285 (2010).
Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).
Christen, S., Peterhans, E. & Stocker, R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc. Natl Acad. Sci. USA 87, 2506–2510 (1990).
Cervenka, I., Agudelo, L. Z. & Ruas, J. L. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science 357, eaaf9794 (2017).
Underwood, E. The final countdown. Science 350, 1188–1190 (2015).
Hausenloy, D. J. et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N. Engl. J. Med. 373, 1408–1417 (2015).
Garg, A. X. et al. Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. JAMA 311, 2191–2198 (2014).
Ebrahimkhani, M. R. et al. Aag-initiated base excision repair promotes ischemia reperfusion injury in liver, brain, and kidney. Proc. Natl Acad. Sci. USA 111, E4878–4886 (2014).
Langholz, B. & Goldstein, L. Risk set sampling in epidemiologic cohort studies. Stat. Sci. 11, 35–53 (1996).
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2, 1–138 (2012).
Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease classification system. Crit. Care Med. 13, 818–829 (1985).
Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Acknowledgements
This randomized clinical trial was funded by an Innovation Grant from the BIDMC awarded to A.P.M. and K.R.K. K.M.R., V.W., A.K., and M.R.L. were supported by T32DK007199; D.E.L. by K23DK106448; C.C.K. and R.I.T. by T32DK007540; S.J.H. by K23AG042459; N.S.-T. by a grant from Assistance Publique—Hôpitaux de Paris; and A.H.B. by K08HL121801 and R56HL133399. Work in S.M.P.’s laboratory was supported by R35HL139424, R01HL125275, and R01DK095072.
Author information
Authors and Affiliations
Contributions
A.P.M. and K.R.K. were co-principal investigators on the phase 1 pilot study of oral NAM in cardiac surgery patients for which V.W., J.M., A.L., and M.E.T. were coinvestigators. S.J.H. served as the independent medical monitor for this trial. K.M.R., N.S.-T., and A.H.B. analyzed samples and data from all human studies. A.H.B. developed targeted metabolic assays and conducted all related measurements. M.T.T. conducted the mouse studies and analyzed the results with assistance from N.S.-T. and M.R.L. D.E.L. and S.S.W. enrolled the ICU cohort, created that repository, and performed statistical analyses of the uQ/T results in the ICU cohort. A.K. and S.H.K. enrolled the discovery cohort of cardiac surgery patients and created that repository with guidance from S.M.P. C.C.K., E.P.R., and R.I.T. developed and conducted the trial of oral NAM in healthy volunteers. E.P.R. also conducted metabolomic screening of mouse samples on the platform developed in C.B.C.’s laboratory with input from C.B.C. A.P.M., M.T.T., K.M.R., and S.M.P. assumed primary responsibility for writing the manuscript. All authors reviewed, provided substantive input, and approved of the final manuscript.
Corresponding author
Ethics declarations
Competing interests
S.M.P. is listed as an inventor on disclosures filed by BIDMC pertaining to NAD+.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Supplementary Text and Figures
Supplementary Figures 1–7 and Supplementary Tables 1–12
Rights and permissions
About this article
Cite this article
Poyan Mehr, A., Tran, M.T., Ralto, K.M. et al. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med 24, 1351–1359 (2018). https://doi.org/10.1038/s41591-018-0138-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0138-z
- Springer Nature America, Inc.
This article is cited by
-
Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism
Cell Communication and Signaling (2024)
-
Selenium nanoparticles alleviate renal ischemia/reperfusion injury by inhibiting ferritinophagy via the XBP1/NCOA4 pathway
Cell Communication and Signaling (2024)
-
Regulation of and challenges in targeting NAD+ metabolism
Nature Reviews Molecular Cell Biology (2024)
-
Mitochondrial metabolism and targeted treatment strategies in ischemic-induced acute kidney injury
Cell Death Discovery (2024)
-
Tubular insulin-induced gene 1 deficiency promotes NAD+ consumption and exacerbates kidney fibrosis
EMBO Molecular Medicine (2024)